160 related articles for article (PubMed ID: 17545554)
1. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Ural AU; Avcu F
Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
[No Abstract] [Full Text] [Related]
2. Treatment for myeloma bone disease.
Yeh HS; Berenson JR
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
[TBL] [Abstract][Full Text] [Related]
3. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
4. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy.
Kleber M; Udi J; Metzke B; Terpos E; Roodmann GD; Morgan G; Dispenzieri A; Einsele H; Wäsch R; Engelhardt M
Leuk Lymphoma; 2012 Jun; 53(6):1057-61. PubMed ID: 22149167
[TBL] [Abstract][Full Text] [Related]
5. [Integrated supportive therapy for multiple myeloma-bone disease treatment, myeloma kidney treatment, cryotherapy, nutrition support team].
Miwa A
Nihon Rinsho; 2012 Apr; 70 Suppl 2():603-27. PubMed ID: 23134022
[No Abstract] [Full Text] [Related]
6. Bisphosphonate therapy in the treatment of multiple myeloma.
Lawson MA; Ashcroft J; Croucher PI
Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
[TBL] [Abstract][Full Text] [Related]
7. Optimal use of bisphosphonates in patients with multiple myeloma.
Terpos E; Roodman GD; Dimopoulos MA
Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
[No Abstract] [Full Text] [Related]
8. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ; Raje NS
Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
[TBL] [Abstract][Full Text] [Related]
9. [Effect of bisphosphonate on myeloma bone disease].
Abe M; Matsumoto T; Kosaka M
Rinsho Ketsueki; 2002 May; 43(5):349-52. PubMed ID: 12096484
[No Abstract] [Full Text] [Related]
10. [Management of bone lesions in multiple myeloma].
Hata H; Mitsuya H
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524
[TBL] [Abstract][Full Text] [Related]
11. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
Anderson K; Ismaila N; Kyle RA
J Oncol Pract; 2018 Apr; 14(4):266-269. PubMed ID: 29517956
[No Abstract] [Full Text] [Related]
12. Molecular mechanisms, current management and next generation therapy in myeloma bone disease.
Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J
Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
14. Atraumatic bone pain in multiple myeloma secondary to bisphosphonate-related bone injury.
Williams R; Wolger L; Alajangi R
Br J Haematol; 2021 Jan; 192(2):229. PubMed ID: 33094837
[No Abstract] [Full Text] [Related]
15. Supportive therapy in multiple myeloma.
Ludwig H; Zojer N
Recent Results Cancer Res; 2011; 183():307-33. PubMed ID: 21509692
[TBL] [Abstract][Full Text] [Related]
16. Current Controversies in the Management of Myeloma Bone Disease.
Silbermann R; Roodman GD
J Cell Physiol; 2016 Nov; 231(11):2374-9. PubMed ID: 26910829
[TBL] [Abstract][Full Text] [Related]
17. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
Pochintesta L; Mangiacavalli S; Cocito F; Pompa A; Albertini R; Pascutto C; Ferretti VV; Cazzola M; Corso A
Leuk Lymphoma; 2014 Jun; 55(6):1397-8. PubMed ID: 23931337
[No Abstract] [Full Text] [Related]
18. Management of Myeloma Bone Lesions.
Du JS; Yen CH; Hsu CM; Hsiao HH
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
[TBL] [Abstract][Full Text] [Related]
19. Updates in the treatment of multiple myeloma.
Berenson JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):667-9. PubMed ID: 23187773
[No Abstract] [Full Text] [Related]
20. Novel therapeutic targets in myeloma bone disease.
Webb SL; Edwards CM
Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
